SCHEMBL23301382

SCHEMBL23301382

CCOC(=O)c1cnc(Cl)cc1N[C@@H]1CCCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK3 P52333 7/20 0.48
▸ JAK1 P23458 5/20 0.48
▸ TP53 P04637 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ LMNA P02545 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ USP30 Q70CQ3 2/20 0.42
▸ BRD4 O60885 1/20 0.42
▸ ANO1 Q5XXA6 1/20 0.41
▸ GPR119 Q8TDV5 1/20 0.41
▸ CNR1 P21554 1/20 0.41
▸ CNR2 P34972 1/20 0.41
▸ PDE4B Q07343 2/20 0.41
▸ PIM1 P11309 2/20 0.41
▸ PIM2 Q9P1W9 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29894215 1.00 JAK3 (0.48) JAK3JAK1TP53POLBMEN1
SCHEMBL23301595 1.00 JAK3 (0.48) JAK3JAK1TP53POLBMEN1
SCHEMBL29894216 1.00 JAK3 (0.48) JAK3JAK1TP53POLBMEN1
SCHEMBL23301573 0.97 JAK3 (0.46) JAK3JAK1TP53POLBMEN1
SCHEMBL23301627 0.97 JAK3 (0.46) JAK3JAK1TP53POLBMEN1
SCHEMBL21389956 0.95 TP53 (0.48) JAK3JAK1TP53POLBMEN1
SCHEMBL30194483 0.95 TP53 (0.48) JAK3JAK1TP53POLBMEN1
SCHEMBL23301567 0.95 TP53 (0.48) JAK3JAK1TP53POLBMEN1
SCHEMBL29894376 0.95 TP53 (0.48) JAK3JAK1TP53POLBMEN1
SCHEMBL17119652 0.95 TP53 (0.48) JAK3JAK1TP53POLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4051677-B1 BICYCLIC NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF SALT-INDUCED KINASE SIK2 CANCER RESEARCH TECH LTD (GB) 2026-03-18 — — EP disclosed
US-12509457-B2 Bicyclic nitrogen containing heterocycles as inhibitors of salt-induced kinase SIK2 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2025-12-30 — — US disclosed
US-20230014742-A1 BICYCLIC NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF SALT-INDUCED KINASE SIK2 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-01-19 — — US disclosed
US-20230014742-A1 BICYCLIC NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF SALT-INDUCED KINASE SIK2 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-01-19 — — US disclosed
WO-2021084266-A1 BICYCLIC NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF SALT-INUCED KINASE SIK2 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230014742-A1 BICYCLIC NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF SALT-INDUCED KINASE SIK2 SIK2, SIK1, SIK3 JAK3 91/4885JAK1 60/4885TP53 1146/4885
US-12509457-B2 Bicyclic nitrogen containing heterocycles as inhibitors of salt-induced kinase SIK2 SIK2, SIK1, SIK3 JAK3 129/4885JAK1 61/4885TP53 2134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback